These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1017 related articles for article (PubMed ID: 16733218)

  • 61. Demonstration of EGFR gene copy loss in colorectal carcinomas by fluorescence in situ hybridization (FISH): a surrogate marker for sensitivity to specific anti-EGFR therapy?
    Sauer T; Guren MG; Noren T; Dueland S
    Histopathology; 2005 Dec; 47(6):560-4. PubMed ID: 16324192
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Detection of c-kit-activating mutations in gastrointestinal stromal tumors by high-resolution amplicon melting analysis.
    Willmore C; Holden JA; Zhou L; Tripp S; Wittwer CT; Layfield LJ
    Am J Clin Pathol; 2004 Aug; 122(2):206-16. PubMed ID: 15323137
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Gene amplification of ERBB2 and EGFR in adenocarcinoma in situ and intramucosal adenocarcinoma of Barrett's esophagus.
    Ooi A; Zen Y; Ninomiya I; Tajiri R; Suzuki S; Kobayashi H; Imoto I; Dobashi Y
    Pathol Int; 2010 Jun; 60(6):466-71. PubMed ID: 20518902
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas.
    Taniguchi K; Uchida J; Nishino K; Kumagai T; Okuyama T; Okami J; Higashiyama M; Kodama K; Imamura F; Kato K
    Clin Cancer Res; 2011 Dec; 17(24):7808-15. PubMed ID: 21976538
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification.
    Angulo B; Suarez-Gauthier A; Lopez-Rios F; Medina PP; Conde E; Tang M; Soler G; Lopez-Encuentra A; Cigudosa JC; Sanchez-Cespedes M
    J Pathol; 2008 Feb; 214(3):347-56. PubMed ID: 17992665
    [TBL] [Abstract][Full Text] [Related]  

  • 66. High epidermal growth factor receptor amplification rate but low mutation frequency in Middle East lung cancer population.
    Al-Kuraya K; Siraj AK; Bavi P; Al-Jommah N; Ezzat A; Sheikh S; Amr S; Al-Dayel F; Simon R; Guido S
    Hum Pathol; 2006 Apr; 37(4):453-7. PubMed ID: 16564920
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Genetic evolution of epidermal growth factor receptor in adenocarcinoma with a bronchioloalveolar carcinoma component.
    Zhong WZ; Wu YL; Yang XN; Guo AL; Su J; Zhang XC; Luo DL; Wang Z; Chen HJ; Zhou Q; Xu CR; Qiao GB; Liao RQ; Yang JJ; Mok TS
    Clin Lung Cancer; 2010 May; 11(3):160-8. PubMed ID: 20439191
    [TBL] [Abstract][Full Text] [Related]  

  • 68. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.
    Hashimoto T; Tokuchi Y; Hayashi M; Kobayashi Y; Nishida K; Hayashi S; Ishikawa Y; Tsuchiya S; Nakagawa K; Hayashi J; Tsuchiya E
    Cancer Res; 1999 Nov; 59(21):5572-7. PubMed ID: 10554037
    [TBL] [Abstract][Full Text] [Related]  

  • 69. EGFR expression and gene copy number in triple-negative breast carcinoma.
    Gumuskaya B; Alper M; Hucumenoglu S; Altundag K; Uner A; Guler G
    Cancer Genet Cytogenet; 2010 Dec; 203(2):222-9. PubMed ID: 21156237
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Deregulation of EGFR/VEGF/HIF-1a signaling pathway in colon adenocarcinoma based on tissue microarrays analysis.
    Rigopoulos DN; Tsiambas E; Lazaris AC; Kavantzas N; Papazachariou I; Kravvaritis C; Tsounis D; Koliopoulou A; Athanasiou AE; Karameris A; Manaios L; Sergentanis TN; Patsouris E
    J BUON; 2010; 15(1):107-15. PubMed ID: 20414936
    [TBL] [Abstract][Full Text] [Related]  

  • 71. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases.
    Schmid K; Oehl N; Wrba F; Pirker R; Pirker C; Filipits M
    Clin Cancer Res; 2009 Jul; 15(14):4554-60. PubMed ID: 19584155
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Use of mutation specific antibodies to detect EGFR status in small biopsy and cytology specimens of lung adenocarcinoma.
    Hasanovic A; Ang D; Moreira AL; Zakowski MF
    Lung Cancer; 2012 Aug; 77(2):299-305. PubMed ID: 22542171
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Unique p53 and epidermal growth factor receptor gene mutation status in 46 pulmonary lymphoepithelioma-like carcinomas.
    Chang YL; Wu CT; Shih JY; Lee YC
    Cancer Sci; 2011 Jan; 102(1):282-7. PubMed ID: 21070477
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Aneusomy of chromosomes 7, 8, and 17 and amplification of HER-2/neu and epidermal growth factor receptor in Gleason score 7 prostate carcinoma: a differential fluorescent in situ hybridization study of Gleason pattern 3 and 4 using tissue microarray.
    Skacel M; Ormsby AH; Pettay JD; Tsiftsakis EK; Liou LS; Klein EA; Levin HS; Zippe CD; Tubbs RR
    Hum Pathol; 2001 Dec; 32(12):1392-7. PubMed ID: 11774175
    [TBL] [Abstract][Full Text] [Related]  

  • 75. EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients.
    Tang X; Shigematsu H; Bekele BN; Roth JA; Minna JD; Hong WK; Gazdar AF; Wistuba II
    Cancer Res; 2005 Sep; 65(17):7568-72. PubMed ID: 16140919
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Polysomy of chromosome 17 in breast cancer tumors showing an overexpression of ERBB2: a study of 175 cases using fluorescence in situ hybridization and immunohistochemistry.
    Salido M; Tusquets I; Corominas JM; Suarez M; Espinet B; Corzo C; Bellet M; Fabregat X; Serrano S; Solé F
    Breast Cancer Res; 2005; 7(2):R267-73. PubMed ID: 15743507
    [TBL] [Abstract][Full Text] [Related]  

  • 77. EGFR mutant-specific immunohistochemistry has high specificity and sensitivity for detecting targeted activating EGFR mutations in lung adenocarcinoma.
    Cooper WA; Yu B; Yip PY; Ng CC; Lum T; Farzin M; Trent RJ; Mercorella B; Clarkson A; Kohonen-Corish MR; Horvath LG; Kench JG; McCaughan B; Gill AJ; O'Toole SA
    J Clin Pathol; 2013 Sep; 66(9):744-8. PubMed ID: 23757037
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Color multiplex polymerase chain reaction for quantitative analysis of epidermal growth factor receptor genes in colorectal adenocarcinoma.
    Layfield LJ; Bernard PS; Goldstein NS
    J Surg Oncol; 2003 Aug; 83(4):227-31. PubMed ID: 12884235
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Silver-enhanced in situ hybridization for determination of EGFR copy number alterations in non-small cell lung cancer.
    Wulf MA; Bode B; Zimmermann D; Rufibach K; Weder W; Moch H; Soltermann A; Tischler V
    Am J Surg Pathol; 2012 Dec; 36(12):1801-8. PubMed ID: 23154768
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study.
    Hicks DG; Yoder BJ; Pettay J; Swain E; Tarr S; Hartke M; Skacel M; Crowe JP; Budd GT; Tubbs RR
    Hum Pathol; 2005 Apr; 36(4):348-56. PubMed ID: 15891995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 51.